Nasser Nicola J, Klein Jonathan, Agbarya Abed
Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York.
Institute of Oncology, Bnai Zion Medical Center, Haifa, Israel.
Adv Radiat Oncol. 2020 Oct 27;6(1):100603. doi: 10.1016/j.adro.2020.10.016. eCollection 2021 Jan-Feb.
The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.
局限性前列腺癌的主要治疗方式是手术和放疗。手术会切除整个前列腺腺体，而放疗时，受照射的前列腺仍留在患者体内。前列腺特异性生物标志物在手术后应无法检测到，但使用放疗时情况并非如此，因为残留的前列腺细胞可能仍具有代谢活性。在此，我们综述了前列腺癌患者中放疗毒性和反应的肿瘤标志物的作用，包括前列腺特异性抗原、人激肽释放酶2、骨桥蛋白、前列腺癌相关蛋白3、瓜氨酸等。
